$740M deal ends COVID-19 vaccine feud between CureVac and BioNTech

Payout and licensing deal grants US rights to COVID-19 and flu products | Agreement paves way for BioNTech’s $1.25 billion acquisition of CureVac.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

GSK: Pfizer, BioNTech ‘reaped billions of dollars’ from stealing COVID-19 patents

26 April 2024 New claim from GlaxoSmithKline is latest in litany of lawsuits against rivals | US lawsuit, potentially worth “billions of dollars”, is filed as UK trial kicks off between Moderna, Pfizer and BioNTech.

Big Pharma

BioNTech wins latest round in Covid-19 patent clash

21 December 2023 CureVac suffers a blow following a favourable earlier opinion delivered by the German Federal Patent Court | Decision invalidates a patent related to mRNA tech.

Big Pharma

CureVac sues BioNTech over mRNA technology

7 July 2022 Germany-based CureVac has accused BioNTech of infringing four patents related to messenger ribonucleic acid technology.